Search

Displaying results 1761 - 1770 of 9314 in total
  1. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. … [A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006.

  2. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    It is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

  3. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for … [A191688,A191721] The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.

  4. Drug

    Propoxycaine

    go.drugbank.com/drugs/DB09342
    Approved

    This drug was removed from the US market in 1996. … Although no longer available in the United States, this medication was used in combination with procaine to aid in anesthesia during dental procedures [L1592].

  5. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency. … [A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter

  6. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    It is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.

  7. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profi...

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.

  9. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. … The FDA approved ketamine (Ketalar) in 1970.

  10. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other